News

Pharmaceutical Technology53m
Sarepta refuses to pull gene therapy despite FDA order
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.
Stock market today: Dow, S&P 500, Nasdaq jump to start busy week of Big Tech-dominated earnings
US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...
Precision Medicine Online46m
Sarepta to Continue to Ship Duchenne Gene Therapy Elevidys Despite FDA Request
The FDA requested Sarepta voluntarily stop distributing Elevidys after the death of a third patient who received one of the firm's gene therapies.
Wall Street rises toward records as Verizon begins a big week for profit reports with a beat
Verizon Communications helped lead the way and rose 4.8%. The telecom reported a stronger profit for the latest quarter than ...
Fierce Biotech28m
Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...
Becker's Hospital Review46m
Sarepta to continue shipping gene therapy despite patient deaths
Sarepta Therapeutics said it will continue shipping its gene therapy Elevidys for Duchenne muscular dystrophy patients despite an FDA request to pause distribution following multiple patient deaths.
U.S. stock market hits fresh record highs—Dow, S&P 500, Nasdaq climb, driven by Verizon, Block, Cleveland‑Cliffs gains
US Stock market today saw the Dow, S&P 500, and Nasdaq inch higher as Wall Street kicked off a packed week of Big Tech earnings and rising concerns over President Trump's upcoming tariffs. The S&P 500 ...